Faik İlIk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Faik İlIk has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Devrimsel Harika Ertem
Silivri Anadolu Hospital, Department of Pain Management, Istanbul, Türkiye
2 shared publications - Celal Ilker Basarir
Sisli Hamidiye Etfal Training & Res Hosp, Dept Neurol, Istanbul, Turkey
1 shared publication - Gözde Baran
Department of Neurology, University of Health Sciences, Hamidiye Faculty of Medicine, Sancaktepe Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Türkiye
1 shared publication - Mustafa Kemal İlIk
Büyükşehir Hospital, Department of Neurosurgery, Konya, Türkiye
1 shared publication - N. Gonderten
University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Neurology
1 shared publication
Latest Publications
- 1 January 2026
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 79 (1-2) , 45-52
The efficacy of Gasserian ganglion block and pulsed radiofrequency in the treatment of chronic cluster headache: A retrospective cohort study
Background and purpose To assess the effectiveness of Gasserian ganglion block and pulsed radiofrequency in managing chronic cluster headache (CCH). Methods We enrolled 38 patients with treatment-resistant CCH who were admitted between March 2020 and January 2024 and underwent Gasserian ganglion pulsed radiofrequency (PRF) combined with a ganglion block. Patients were followed up for six months, with pain severity assessed using the 0-10 Numerical Pain Rating Scale (NPRS). Results Among 38 patients (mean age 30.8 ± 8.6 years), the mean headache duration before treatment was 29.72 ± 17.65 months, and patients reported an average of 19.11 ± 2.01 headache days per month. Before the procedure, the mean NPRS score was 8.81 ± 0.80, which significantly decreased to 4.13 ± 3.74 post-treatment (p=0.001) and further declined to 3.38 ± 1.59 at the six-month follow-up (p=0.002). Four patients became pain-free, while 13 did not benefit from the procedure. The mean number of headache days dropped to 6.40 ± 4.22 per month (p<0.001). Additionally, 24 patients required lower doses or fewer preventive medications, suggesting a sustained therapeutic benefit. The procedure had mild and temporary side effects, including pain on the day of injection, and localized discomfort. No serious complications were reported. Conclusion Our results showed a significant reduction in pain and attack frequency with Gasserian ganglion block and PRF for treating CCH resistant to standard therapies, with many patients requiring less medication. The procedure was well-tolerated, with mild and temporary side effects; these findings suggest it may be a promising option for drug-resistant CCH. Future studies should include controlled trials for further evaluation.
- 1 January 2026
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 79 (1-2) , 45-52
The efficacy of Gasserian ganglion block and pulsed radiofrequency in the treatment of chronic cluster headache: A retrospective cohort study
Background and purpose To assess the effectiveness of Gasserian ganglion block and pulsed radiofrequency in managing chronic cluster headache (CCH). Methods We enrolled 38 patients with treatment-resistant CCH who were admitted between March 2020 and January 2024 and underwent Gasserian ganglion pulsed radiofrequency (PRF) combined with a ganglion block. Patients were followed up for six months, with pain severity assessed using the 0-10 Numerical Pain Rating Scale (NPRS). Results Among 38 patients (mean age 30.8 ± 8.6 years), the mean headache duration before treatment was 29.72 ± 17.65 months, and patients reported an average of 19.11 ± 2.01 headache days per month. Before the procedure, the mean NPRS score was 8.81 ± 0.80, which significantly decreased to 4.13 ± 3.74 post-treatment (p=0.001) and further declined to 3.38 ± 1.59 at the six-month follow-up (p=0.002). Four patients became pain-free, while 13 did not benefit from the procedure. The mean number of headache days dropped to 6.40 ± 4.22 per month (p<0.001). Additionally, 24 patients required lower doses or fewer preventive medications, suggesting a sustained therapeutic benefit. The procedure had mild and temporary side effects, including pain on the day of injection, and localized discomfort. No serious complications were reported. Conclusion Our results showed a significant reduction in pain and attack frequency with Gasserian ganglion block and PRF for treating CCH resistant to standard therapies, with many patients requiring less medication. The procedure was well-tolerated, with mild and temporary side effects; these findings suggest it may be a promising option for drug-resistant CCH. Future studies should include controlled trials for further evaluation.
- Open Access
- 17 September 2019
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 7 (3) , 139-145
Opioids and Migraine: Opioid Awareness and Frequency of Use among Turkish Migraineurs
Despite the inadequate evidence of effi cacy and safety of opioid use for the treatment of migraine, it has been reported that patients with moderate to severe migraine headaches are prescribed opioids. Migraineurs may experience serious health impacts from opioids such as headache-related disability, psychiatric and cardiovascular comorbidities. The reduction of the risk of opioid abuse and prevention of an opioid epidemic are important public health challenges. The aim of this study was to assess the awareness of opioid therapy for migraine and the frequency of use among Turkish patients with episodic and chronic migraine. Materials and methods: consecutive migraine patients were enrolled in this cross-sectional study. A semi-structured questionnaire was developed and used by the researchers to assess the patients’ awareness of an opiod treatment option and the frequency of use of opioids for migraine treatment. Results. One hundred two patients were enrolled, of which 72 had episodic migraine and 30 had chronic migraine. All subjects reported that they had not been offered or prescribed any kind of opioids by general practitioners and neurologists for their headache. Besides, only 7 % of patients declared that they had heard of opioid treatment for migraine but they had never consulted their doctors about its effects. Conclusions. Our fi ndings demonstrated that opioids were not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians. The reduction of opioid prescription will help to prevent the development of medication overuse and opiate-induced headaches and drug addiction.
- 17 September 2019
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 7 (3) , 139-145
Open AccessOpioids and Migraine: Opioid Awareness and Frequency of Use among Turkish Migraineurs
Despite the inadequate evidence of effi cacy and safety of opioid use for the treatment of migraine, it has been reported that patients with moderate to severe migraine headaches are prescribed opioids. Migraineurs may experience serious health impacts from opioids such as headache-related disability, psychiatric and cardiovascular comorbidities. The reduction of the risk of opioid abuse and prevention of an opioid epidemic are important public health challenges. The aim of this study was to assess the awareness of opioid therapy for migraine and the frequency of use among Turkish patients with episodic and chronic migraine. Materials and methods: consecutive migraine patients were enrolled in this cross-sectional study. A semi-structured questionnaire was developed and used by the researchers to assess the patients’ awareness of an opiod treatment option and the frequency of use of opioids for migraine treatment. Results. One hundred two patients were enrolled, of which 72 had episodic migraine and 30 had chronic migraine. All subjects reported that they had not been offered or prescribed any kind of opioids by general practitioners and neurologists for their headache. Besides, only 7 % of patients declared that they had heard of opioid treatment for migraine but they had never consulted their doctors about its effects. Conclusions. Our fi ndings demonstrated that opioids were not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians. The reduction of opioid prescription will help to prevent the development of medication overuse and opiate-induced headaches and drug addiction.